Suppr超能文献

推进艾滋病毒耐药性技术与策略:来自南非经验的见解及资源有限环境下的未来方向

Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa's Experience and Future Directions for Resource-Limited Settings.

作者信息

Steegen Kim, van Zyl Gert U, Claassen Mathilda, Khan Aabida, Pillay Melendhran, Govender Subitha, Bester Phillip A, van Straaten Johanna M, Kana Vibha, Cutler Ewaldé, Kalimashe Monalisa N, Lebelo Ramokone L, Moloi Mokopi B H, Hans Lucia

机构信息

Department of Molecular Medicine and Haematology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Hospital, Johannesburg 2193, South Africa.

Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.

出版信息

Diagnostics (Basel). 2023 Jun 29;13(13):2209. doi: 10.3390/diagnostics13132209.

Abstract

Monitoring of HIV drug resistance (HIVDR) remains critical for ensuring countries attain and sustain the global goals for ending HIV as a public health threat by 2030. On an individual patient level, drug resistance results assist in ensuring unnecessary treatment switches are avoided and subsequent regimens are tailored on a case-by-case basis, should resistance be detected. Although there is a disparity in access to HIVDR testing in high-income countries compared to low- and middle-income countries (LMICS), more LMICs have now included HIVDR testing for individual patient management in some groups of patients. In this review, we describe different strategies for surveillance as well as where HIVDR testing can be implemented for individual patient management. In addition, we briefly review available technologies for HIVDR testing in LMICs, including Sanger sequencing, next-generation sequencing, and some point-of-care options. Finally, we describe how South Africa has implemented HIVDR testing in the public sector.

摘要

监测艾滋病毒耐药性(HIVDR)对于确保各国实现并维持到2030年将艾滋病毒作为公共卫生威胁消除的全球目标仍然至关重要。在个体患者层面,耐药性检测结果有助于避免不必要的治疗方案切换,并在检测到耐药性时根据具体情况定制后续治疗方案。尽管与低收入和中等收入国家(LMICs)相比,高收入国家在获得HIVDR检测方面存在差距,但现在更多的低收入和中等收入国家已将HIVDR检测纳入某些患者群体的个体患者管理中。在本综述中,我们描述了不同的监测策略以及可在何处实施HIVDR检测以进行个体患者管理。此外,我们简要回顾了低收入和中等收入国家可用的HIVDR检测技术,包括桑格测序、下一代测序和一些即时检测选项。最后,我们描述了南非如何在公共部门实施HIVDR检测。

相似文献

2
HIV-1 drug resistance and resistance testing.
Infect Genet Evol. 2016 Dec;46:292-307. doi: 10.1016/j.meegid.2016.08.031. Epub 2016 Aug 29.
3
Determinants of HIV drug resistance and public health implications in low- and middle-income countries.
Antivir Ther. 2012;17(6):941-53. doi: 10.3851/IMP2320. Epub 2012 Aug 16.
4
HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study.
PLoS One. 2017 Dec 15;12(12):e0188606. doi: 10.1371/journal.pone.0188606. eCollection 2017.
5
8
Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials.
Pathogens. 2022 Jun 25;11(7):724. doi: 10.3390/pathogens11070724.

本文引用的文献

1
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
J Acquir Immune Defic Syndr. 2023 Apr 15;92(5):422-429. doi: 10.1097/QAI.0000000000003157.
2
BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.
HIV Med. 2022 Dec;23 Suppl 5:3-115. doi: 10.1111/hiv.13446.
4
Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials.
Pathogens. 2022 Jun 25;11(7):724. doi: 10.3390/pathogens11070724.
5
6
Dolutegravir Resistance in Malawi's National HIV Treatment Program.
Open Forum Infect Dis. 2022 Apr 5;9(5):ofac148. doi: 10.1093/ofid/ofac148. eCollection 2022 May.
8
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793.
9
HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa.
J Glob Antimicrob Resist. 2022 Jun;29:468-475. doi: 10.1016/j.jgar.2021.10.023. Epub 2021 Nov 14.
10
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164521. doi: 10.1128/AAC.01645-21. Epub 2021 Oct 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验